Objective: This observational retrospective study aims to present early
experience with tigecycline (TIG) in the treatment of infections due to
multi-drug resistant (MDR) microorganisms.
Methods: Adult patients included, received TIG for >5 days either as
monotherapy (M group) or as presumed active monotherapy (PAM group). In
the PAM group, all co-administered antimicrobial(s) were resistant in
vitro against the targeted pathogen(s) or had been clinically and
microbiologically failing after >5 days of therapy despite in vitro
susceptibility.
Results: Forty-five patients (35 in ICU) were treated for 28
Acinetobacter baumannii and 23 Klebsiella pneumoniae infections [21
ventilator-associated and healthcare-acquired pneumonia (VAP/HCAP), 10
bloodstream infections (BSI) and 14 surgical infections (SI)].
Successful overall clinical outcome was 80%, i.e. 81.8% in M group,
78.3% in PAM group, 90.5% in VAP/HCAP, 80% in BSI, 64.3% in SI and
85% in the cases with septic shock. Superinfections from
Enterobacteriaceae inherently resistant to tigecycline occurred in
31.8% of M and 13% of PAM group (p<0.001).
Conclusion: TIG represents a promising option in infections from MDR
pathogens, however, further clinical experience is required. (c) 2009
The British Infection Society. Published by Elsevier Ltd. All rights
reserved